Compounded Tirzepatide for Weight Loss & Diabetes
Schedule an appointment with Dr. Sam Kalou to explore the use of Mounjaro® and Zepbound®, compound medications containing tirzepatide, for managing diabetes and weight-related concerns. This potent ingredient effectively regulates blood sugar levels and, when paired with a healthy lifestyle, can result in substantial weight loss. Take the first step towards achieving your health objectives by booking an appointment now.
Self-administered injectable prescription
Helps with weight and blood sugar management
Up to 20.9% reduction in body weight
What is Compounded Tirzepatide?
Tirzepatide has recently gained approval as an effective weight loss medication. This injectable treatment targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, making it popular for its dual function. By mimicking the effects of GLP-1, a hormone crucial for regulating glucose and appetite, tirzepatide helps with weight loss by reducing gastric emptying, promoting a feeling of fullness, and balancing blood sugar levels.
However, tirzepatide is not a miracle solution and requires lifestyle changes for optimal results. These lifestyle changes include regular exercise and a healthy diet, as simply using weight management medications without these changes may only lead to short-term weight loss.
Here are some benefits of tirzepatide:
Revolutionary dual mechanism: Tirzepatide stands out from traditional weight loss approaches by combining both appetite regulation and metabolic enhancement.
Rapid weight loss results: Within a few weeks, you will notice a significant change in your weight, making tirzepatide an ideal option for those seeking quick results.
Clinically supported: Scientific research, rigorous studies, and clinical trials have proven tirzepatide's effectiveness for weight loss, with some individuals losing up to 48 lbs.
Tirzepatide for Weight Loss
Tirzepatide How to Use
Dr. Kalou will provide you with detailed instructions on how to properly use tirzepatide, which is available in a variety of dosage strengths. This medication is typically available in pre-filled injection pens for easy use. Here are some basic guidelines to follow when using tirzepatide:
Tirzepatide should be taken once a week at home, with or without food.
The single-dose pen eliminates the need to handle a needle and makes the injection process easier.
Dr. Kalou will help you determine the best injection site, such as the upper arm, lower stomach, or upper thigh. Before injecting, clean the chosen site with an alcohol swab and allow it to dry. It is recommended to rotate injection sites weekly.
Remove the safety cap and place the flat end of the pen against the skin at the injection site.
To start the injection, unlock the pen by turning the lock ring and hold the purple button for 10 seconds.
After use, dispose of the pen in a designated sharps container.
Tirzepatide side effects
Possible effects of tirzepatide for weight loss may be comparable to those of tirzepatide and other GLP-1s. Side effects that may be associated with Zepbound™ include:
1. Nausea and vomiting
2. Diarrhea or constipation
3. Abdominal pain
4. Mild fatigue and headache
5. Injection site reactions, such as rash, itching, and swelling.
There are also some potential concerns related to tirzepatide, including:
1. Interactions with birth control: Tirzepatide may reduce the effectiveness of oral hormonal birth control. It is recommended to switch to a non-oral form of birth control before beginning Zepbound™.
2. Pancreatitis: There is a risk of pancreatitis associated with Zepbound™.
3. Thyroid tumor: People with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not use tirzepatide due to the potential risk of developing thyroid tumors.
4. Pregnancy and breastfeeding: Tirzepatide should not be used by those planning to become pregnant within the next 3 months or who are currently pregnant or breastfeeding.
If you experience a severe allergic reaction or serious side effects, seek medical attention immediately. Hypoglycemia (low blood sugar) may occur if tirzepatide is taken with insulin or medications that increase insulin levels in the body.
Ongoing research is being conducted regarding the risks of tirzepatide. Currently, there is no long-term safety data available. Continuous monitoring and research will help to establish a more comprehensive understanding of the potential side effects associated with tirzepatide.
Questions Our Patients Ask About Tirzepatide
-
The impacts of tirzepatide typically become noticeable within a couple of weeks, but the exact timeline can differ for each individual.
-
According to the SURMOUNT-1 trial findings, tirzepatide is among the most potent weight loss medications currently available. Its dual mechanisms of action make it more impactful on weight and blood sugar levels compared to GLP-1 agonist drugs like semaglutide and liraglutide, both of which are FDA-approved for managing weight and sugar levels but sold under different trade names. When comparing tirzepatide with these other GLP-1 medications, it appears to be significantly superior in effectiveness. The results showed that 50% of patients on the 10 mg dose and 57% on the 15 mg dose lost over 20% of their body weight, surpassing the long-term weight loss achieved through procedures like lap-band surgeries. This level of weight loss is also within the typical range seen in long-term outcomes of surgeries like the sleeve gastrectomy.
-
Our compounded tirzepatide is available for cash purchase at $200 for one month, $300 for two months, $400 for three months, and $500 for four months. If you order this medication during your appointment, the specified amount will be charged to your card on file. Please ensure that you have a current address and an active card on file to avoid any delays with your prescription.
Our clinic is dedicated to providing accurate information. The information provided is based upon studies published in New England Journal of Medicine, an FDA Press Announcement, the Zepbound™ Official Website, and Lilly Investor News Release.